Floatz logo

trc105

Adenoma, Liver Cell

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adenoma, Liver Cell cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 1/2CCC

Same molecule, other indications

trc105 is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
liver and intrahepatic bile duct neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →